Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3631-3640 Newer>

BusinessWeek April 30, 2007 Catherine Arnst	Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced.
Inc. April 2007 Dalia Fahmy	Personal Pediatrics Wants to Revive the Vanishing Art of the House Call. Investors offer opinions to a company that aims to help pediatricians who want to run a house call practice without a brick-and-mortar office.
The Motley Fool April 17, 2007 Rich Duprey	Eisai Says Sayonara The Japanese company withdraws its application for approval of its Alzheimer's drug for severe cases of the disease in Europe. What will it mean to investors?
The Motley Fool April 17, 2007 Rich Duprey	BioLase Darkens Smiles The dental laser maker warns that quarterly revenues will be dramatically lower. Investors, take note.
The Motley Fool April 17, 2007 Brian Lawler	ImClone Loses an Indication ImClone's lead drug fails in a clinical trial. Investors, take note.
The Motley Fool April 17, 2007 Brian Lawler	Neurochem Must Wait The FDA delays a regulatory decision on Neurochem's lead compound. Investors, take note.
The Motley Fool April 17, 2007 Jack Uldrich	Intuitive Surgical Sells Itself A hospital's mailing on the company's da Vinci Surgical System could boost demand from patients. Investors, take note.
BusinessWeek April 23, 2007 Arlene Weintraub	Under The Weather At J&J Johnson & Johnson's three big products have seen setbacks, with little in sight to replace them.
BusinessWeek April 23, 2007 Alex Halperin	Vioxx Casts A Long, Long Shadow More than two years after Merck & Co. pulled its Vioxx painkiller from shelves over heart attack and stroke risks, the Food & Drug Administration is still skittish about the safety of drugs currently on the market and those coming up for review.
Fast Company May 1, 2007 Michael A. Prospero	Space Shot: Genzyme Center, Cambridge, MA It stands to reason that the biotech company's ecotastic office has become a full-scale model for other architects looking to go green. But it has also turned out to be something of a recruiting tool.
<Older 3631-3640 Newer> Return to current articles.